ANIX Anixa Biosciences Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 715446 · Fiscal year ends 10/31
Financial factors as of 2026-07-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY6.6%
TTM EPS YoY5.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-66.8%
ROA-63.4%
ROIC (approx.)-61.6%
Asset turnover—
Leverage & solvency
Liabilities / assets12.4%
Debt / equity0.00x
Current ratio8.54x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-18.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-10-31 | FY20242024-10-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | $210,000 |
| R&D expense | $5.07M | $6.40M |
| SG&A expense | $6.63M | $7.43M |
| Operating income | -$11.70M | -$13.83M |
| Net income | -$10.93M | -$12.55M |
| EPS (basic) | -0.34 | -0.39 |
| EPS (diluted) | -0.34 | -0.39 |
| Weighted avg. shares (diluted) | 32,454 | 31,898 |
| Balance sheet | ||
| Cash & equivalents | $1.24M | $1.27M |
| Short-term investments | $13.93M | $18.65M |
| Receivables | — | $173,000 |
| Current assets | $15.89M | $21.36M |
| Total assets | $16.08M | $21.59M |
| Current liabilities | $1.97M | $2.50M |
| Total liabilities | $2.13M | $2.70M |
| Shareholders' equity | $15.16M | $20.00M |
| Shares outstanding | 33.01M | 32.20M |
| Cash flow statement | ||
| Operating cash flow | -$7.17M | -$7.33M |
| Investing cash flow | $4.87M | $4.28M |
| Financing cash flow | $2.28M | $3.42M |
| Stock-based compensation | $3.68M | $4.42M |
| Share buybacks | — | $6,000 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.